In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Novavax, Inc’s stock clocked out at $7.68, down -2.41% from its previous closing price of $7.87. In other words, the price has decreased by -$2.41 from its previous closing price. On the day, 3.97 million shares were traded.
Ratios:
To gain a deeper understanding of NVAX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on February 28, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On July 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral but kept the price unchanged to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when King Rachel K. sold 4,150 shares for $9.02 per share. The transaction valued at 37,435 led to the insider holds 14,770 shares of the business.
YOUNG JAMES F sold 5,400 shares of NVAX for $43,200 on Dec 31 ’24. The Director now owns 51,760 shares after completing the transaction at $8.00 per share. On Dec 24 ’24, another insider, YOUNG JAMES F, who serves as the Director of the company, sold 4,600 shares for $8.48 each. As a result, the insider received 39,008 and left with 57,160 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.81.
Stock Price History:
Over the past 52 weeks, NVAX has reached a high of $23.86, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is -9.54%, while the 200-Day Moving Average is calculated to be -32.17%.
Shares Statistics:
A total of 160.42M shares are outstanding, with a floating share count of 146.74M. Insiders hold about 8.77% of the company’s shares, while institutions hold 59.81% stake in the company.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Novavax, Inc (NVAX).The consensus estimate for the next quarter is $0.34, with high estimates of $0.64 and low estimates of $0.13.
Analysts are recommending an EPS of between $2.69 and -$1.65 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is $0.75, with 6.0 analysts recommending between $2.49 and -$0.32.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $64.6M. It ranges from a high estimate of $106.4M to a low estimate of $31.9M. As of the current estimate, Novavax, Inc’s year-ago sales were $93.86MFor the next quarter, 3 analysts are estimating revenue of $174.73M. There is a high estimate of $191.9M for the next quarter, whereas the lowest estimate is $151.8M.
A total of 7 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.1B, while the lowest revenue estimate was $227.92M, resulting in an average revenue estimate of $483.11M. In the same quarter a year ago, actual revenue was $682.16MBased on 6 analysts’ estimates, the company’s revenue will be $555.67M in the next fiscal year. The high estimate is $888.6M and the low estimate is $320.58M.
